A thioredoxin-mimetic tripeptide called CB3 delayed seizure onset, reduced seizure frequency, preserved brain neurons, and improved behavior in mouse models of temporal lobe epilepsy, showing potential as a disease-modifying therapy.
30-40% of patients drug-resistantto current anti-seizure medications, which don't modify disease progression — CB3 peptide showed disease-modifying potential in preclinical models
What the researchers found
In vitro, CB3 pretreatment (50-100 μM) reduced oxidative activity and pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) while increasing anti-inflammatory IL-10 in an epileptiform activity model.
In vivo, early CB3 intervention (20 mg/kg/day, i.p.) after kainic acid-induced status epilepticus significantly delayed seizure onset, reduced seizure frequency and cumulative burden, and preserved hippocampal neuronal integrity. Treated mice showed improved locomotor activity, reduced anxiety, and better spatial working memory. In established chronic epilepsy, CB3 (20 mg/kg/day) produced sustained reduction in recurrent seizure activity and seizure burden with improvements in anxiety, though memory deficits remained unchanged.
Why it matters
Current anti-seizure medications are purely symptomatic — they suppress seizures but don't prevent epilepsy from developing or worsening. With 30-40% of patients being drug-resistant, there is an urgent need for disease-modifying therapies. CB3 appears to go beyond seizure suppression by targeting the underlying oxidative stress and inflammation that drive disease progression, while also protecting neurons.
How the study worked
The study used complementary in vitro and in vivo approaches. Cell culture models used low-Mg2+-induced epileptiform activity to test CB3's effects on oxidative stress and inflammation. In vivo, kainic acid-induced status epilepticus in mice modeled temporal lobe epilepsy. CB3 was tested both as early intervention (started after initial seizures) and in established chronic epilepsy. Outcomes included seizure monitoring, hippocampal histology, and behavioral assessments (locomotion, anxiety, spatial memory).
What this study cannot tell us
All experiments were conducted in mice; translation to human epilepsy patients is uncertain. Memory and learning deficits were not improved by CB3 in the chronic epilepsy model, suggesting some established damage may be irreversible. The study used intraperitoneal injection, and oral bioavailability is not addressed. Long-term safety data and optimal dosing for human use would need extensive further study.
How to read the evidence
This is a comprehensive preclinical study using both in vitro and in vivo models of epilepsy with multiple outcome measures (seizures, histology, behavior). While the evidence is strong for a preclinical study, human clinical trials are needed.
When this study was published
Published in 2026 in Redox Biology, this is a very recent study presenting novel findings about a peptide-based disease-modifying approach to epilepsy.
The bigger picture
This study represents an important advance in the search for true disease-modifying epilepsy therapies. By targeting oxidative stress and neuroinflammation — two drivers of epileptogenesis — rather than just suppressing neuronal excitability, CB3 addresses the root causes of disease progression. The thioredoxin-mimetic approach could have implications beyond epilepsy for other neurological conditions where oxidative stress plays a central role.
Questions still open
- Could CB3 be combined with existing anti-seizure medications for additive or synergistic disease-modifying effects?
- Is CB3 orally bioavailable, or would alternative delivery methods be needed for clinical use?
- Would earlier intervention (before the first seizure, in at-risk patients) provide even greater disease prevention?
Common questions
How is CB3 different from current epilepsy medications?
Could CB3 help drug-resistant epilepsy patients?
Read the original research
Thioredoxin-mimetic peptide attenuates epilepsy progression and neurocognitive deficits.
Redox biology, 90, 104021
Citation
Singh, Prince Kumar; Maurya, Shweta; Saadi, Aseel; Sandouka, Sereen; Zhang, Taige; Kadosh, Orya; Sheeni, Yara; Martin, Valeria; Atlas, Daphne; Shekh-Ahmad, Tawfeeq. (2026). Thioredoxin-mimetic peptide attenuates epilepsy progression and neurocognitive deficits.. Redox biology, 90, 104021. https://doi.org/10.1016/j.redox.2026.104021